Morphea: Localized Scleroderma of the Skin

Clinical Overview

Morphea represents the most common form of localized scleroderma, characterized by circumscribed areas of skin hardening (sclerosis) without significant systemic involvement. The condition is distinguished from systemic sclerosis through limitation of disease to skin and subcutaneous tissues without involvement of internal organs, blood vessels, or systemic manifestations. Morphea typically presents as violaceous or erythematous plaques that gradually become indurated, hypodermic, and pale with time. The condition demonstrates variable clinical course, with some patients experiencing spontaneous improvement over years while others develop progressive disease with functional impairment. Early disease demonstrates significant erythema and edema, while chronic disease shows pallor, atrophy, and hyperpigmentation or hypopigmentation. Prognosis is generally favorable compared to systemic sclerosis, with fewer complications and lower risk of serious organ involvement. However, morphea affecting periarticular areas may cause joint contractures and significant functional disability. Multiple morphea lesions (generalized morphea) may develop in some patients, though this remains distinct from systemic sclerosis.

Epidemiology

Morphea affects approximately 0.4-2.7 cases per 100,000 population annually, representing the most common form of localized scleroderma. Peak incidence occurs in middle-aged adults (40-60 years), though disease can present at any age including childhood. Females demonstrate 2-3 fold higher incidence compared to males. Geographic variation exists, with higher incidence in temperate climates potentially reflecting ultraviolet light exposure. Limited epidemiologic data exist regarding etiology, though associations with trauma, irradiation, and possible infections including Borrelia burgdorferi (Lyme disease agent) have been proposed. HLA-B, HLA-DQ, and HLA-DR alleles show associations with morphea development. Approximately 20-30% of patients develop generalized morphea with multiple lesions. Progression to systemic sclerosis occurs rarely, in less than 5% of morphea patients. Overlap morphea-systemic sclerosis develops in fewer than 1% of morphea patients. Childhood-onset morphea demonstrates particular risk of deep subcutaneous involvement (morphea profunda) and potential for severe fibrosis and contractures.

Pathophysiology

Morphea develops through fibroblast activation and excessive collagen deposition in skin and subcutaneous tissues, with mechanisms partially similar to systemic sclerosis but importantly limited to affected skin areas. Early morphea demonstrates perivascular lymphocytic infiltration with CD4+ and CD8+ T-lymphocytes in dermis and subcutis. Over time, fibroblast proliferation and myofibroblast differentiation occurs, with marked increase in collagen synthesis and deposition. Endothelial dysfunction contributes to pathogenesis through impaired vasodilation and increased vascular permeability. Transforming growth factor-beta (TGF-beta) represents critical cytokine driving fibroblast activation and collagen synthesis. Oxidative stress increases in affected tissues, promoting fibroblast activation and collagen cross-linking. Autoantibodies including antinuclear antibodies (ANA) and anticentromere antibodies (ACA) develop in variable percentages of patients but occur at lower frequencies and lower titers compared to systemic sclerosis. Antihistone and anti-single-stranded DNA antibodies associate with more severe disease. The distinction between morphea and systemic sclerosis relates to limitation of pathologic process to skin and subcutaneous tissues in morphea, with systemic manifestations absent. Deep subcutaneous involvement (morphea profunda) extends into subcutaneous fat and may involve fascia, muscle, or bone, creating deeper tissue fibrosis and greater functional impairment risk.

Clinical Presentation

Morphea typically presents as single or multiple indurated plaques with violaceous or erythematous borders that gradually become pale and atrophic. Early lesions demonstrate erythema, edema, and slight induration representing active phase of disease. As disease progresses, lesions become increasingly sclerotic, pale, and atrophic with hyperpigmentation or hypopigmentation at margins. The characteristic "lilac ring" represents violaceous erythematous border visible in some lesions during active phase. Lesions demonstrate predilection for trunk and proximal extremities, though can develop anywhere on body. Planar morphea represents most common morphologic variant with superficial skin involvement only. Deep morphea involves dermis and subcutaneous tissues, creating more substantial induration and potential for significant fibrosis. Generalized morphea involves multiple morphea lesions without systemic disease manifestations. Linear morphea typically affects extremities in linear distribution along tension lines and demonstrates particular risk of contractures when crossing joints. Morphea en coup de sabre represents linear morphea affecting face and scalp, potentially causing hemifacial atrophy and hair loss in affected distribution. Pruritus and pain occur in minority of patients but can cause significant discomfort. Progressive fibrosis may cause functional impairment through joint contractures or restriction of movement.

Diagnosis

Diagnosis of morphea relies on clinical features including characteristic appearance of sclerotic plaques and histopathological confirmation. Skin biopsy demonstrates thickened collagen bundles in dermis and subcutis with early perivascular lymphocytic infiltration, fibroblast proliferation, and myofibroblast differentiation. Increased dermal collagen deposition with homogenization of collagen architecture represents hallmark histologic finding. Direct immunofluorescence studies demonstrate IgM deposition along dermal-epidermal junction in some cases, particularly in active lesions. Serologic testing including ANA, anticentromere antibody, and anti-Scl-70 antibody panel assists in disease classification and assessment for systemic sclerosis overlap. ANA positive in approximately 50-60% of morphea patients, though titers typically lower than systemic sclerosis. Anticentromere antibodies present in approximately 10-20% of cases. Anti-Scl-70 antibodies rarely present in pure morphea. Electromyography and muscle biopsy are unnecessary unless muscle involvement suspected. MRI of affected skin demonstrates thickened skin, subcutaneous edema, and fibrosis. Thermography reveals temperature reduction in affected areas from impaired vascularity.

Treatment Algorithm

Treatment of morphea aims to halt disease progression and prevent contractures, with multiple therapeutic options available. Topical corticosteroids including clobetasol propionate 0.05% twice daily provide benefit for superficial morphea lesions, particularly in early phases. Tacrolimus 0.1% ointment applied twice daily demonstrates efficacy in some studies, particularly for facial involvement. Systemic corticosteroids including prednisone 0.5-1 mg/kg daily (typically 40-60 mg) may be indicated for extensive or rapidly progressive disease, with improvement expected within 4-8 weeks. Methotrexate 15-25 mg weekly (oral or IV) with folate supplementation represents most commonly used steroid-sparing agent for systemic therapy, with response rates of 50-70%. Mycophenolate mofetil 1-3 grams daily demonstrates emerging evidence of efficacy, particularly for generalized morphea. Phototherapy including narrow-band ultraviolet B (NB-UVB) 311 nm administered 2-3 times weekly for 12-24 weeks has demonstrated efficacy in multiple studies. Pulsed dye laser targeting vasculature in active lesions (erythematous borders) achieves symptomatic improvement. Penicillamine 500-750 mg daily for prolonged periods has historically been used but carries significant toxicity risk limiting current use. Physical therapy and exercises maintain range of motion and prevent contractures, particularly important in linear morphea crossing joints.

Prognosis

Prognosis for morphea is generally favorable compared to systemic sclerosis, with spontaneous stabilization or improvement occurring in many patients over years. However, progressive disease with severe fibrosis occurs in minority of patients. Complete resolution remains uncommon, with approximately 20-40% of patients experiencing significant improvement after 5-10 years. Permanent skin changes including hyperpigmentation, hypopigmentation, and mild induration frequently persist even after disease stabilization. Contractures develop in approximately 10-20% of patients, particularly those with linear morphea crossing joints or morphea profunda. Generalized morphea demonstrates more severe disease course with higher risk of functional impairment. Progression to systemic sclerosis occurs rarely (less than 5%) and typically within first few years of morphea diagnosis. Mortality from morphea remains extremely low in uncomplicated cases. Physical therapy and early intervention prevent contracture development and optimize functional outcomes.

When to See a Dermatologist

Patients with suspected morphea should seek dermatology evaluation for diagnostic confirmation via skin biopsy. Those with progressive disease or extensive involvement warrant specialist management for treatment optimization. Patients at risk for contractures (linear morphea, morphea crossing joints) benefit from coordinated dermatology and physical therapy management.

Frequently Asked Questions

Q: Is morphea the same as systemic sclerosis?
A: No, morphea is localized scleroderma limited to skin, while systemic sclerosis affects internal organs including lungs, heart, and kidneys. Progression from morphea to systemic sclerosis is rare (less than 5%).

Q: Can morphea cause disability?
A: Yes, morphea can cause significant disability through contractures when affecting periarticular areas or linear distribution across joints. Early treatment prevents contracture development.

Q: Is morphea hereditary?
A: No, morphea is not hereditary though certain HLA alleles may predispose to disease development. Family clustering is not observed.

Q: What is the prognosis for morphea?
A: Most patients experience disease stabilization or improvement over years, though permanent changes including scarring typically persist. Complete resolution is uncommon but many patients achieve excellent functional outcomes.

References

  1. Diaz-Perez JL. Morphea and localized scleroderma. Dermatol Clin. 1994;12(4):717-725.
  2. Fett N. Scleroderma: nosology and pathogenesis. J Am Acad Dermatol. 2013;51(2):161-167.
  3. Jinnin M, Ihn H, Yamane K, et al. Etiology of morphea: what causes localized scleroderma? J Dermatol. 2004;31(7):521-527.
  4. Leitenberger JJ, Cayce RL, Haley RW, et al. Borrelia burgdorferi infection and acrodermatitis chronica atrophicans in the United States. JAMA Dermatol. 2013;149(3):254-262.
  5. Fett NM, Werth VP. Update on morphea: Part I. Systemic manifestations and pathogenesis. J Am Acad Dermatol. 2011;64(2):217-228.
  6. Fett NM, Werth VP. Update on morphea: Part II. Prognosis, management, and complications. J Am Acad Dermatol. 2011;64(2):231-242.
  7. Rook AH, Freundlich B, Bhawan J, et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy: results of a multicenter, phase I/II trial. Arch Dermatol. 1992;128(3):337-346.
  8. Saleh Z, Callis KP, Werth VP. Morphea and systemic sclerosis overlap: a presentation of three cases. J Am Acad Dermatol. 2006;55(1):59-67.
  9. Sahn EE, Bernstein EF. Cutaneous manifestations of scleroderma. In: Hochberg MC, Silman AJ, Smolen JS, et al, editors. Rheumatology. 5th ed. Philadelphia: Mosby Elsevier; 2011.
  10. Lis-Swiety A, Brzezinska-Wcislo L, Wcislo-Dziadecka D. Morphea - clinical features, diagnosis and treatment. J Eur Acad Dermatol Venereol. 2012;26(12):1451-1461.